Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | SLCO1B3 | Q9NPD5 | 1/20 | 0.51 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23966332 | 0.89 | TDP1 (0.59) | TDP1MAPK1ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL26501099 | 0.89 | TDP1 (0.59) | TDP1MAPK1LMNASMN1; SMN2EPHX2 | |
| SCHEMBL2841624 | 0.89 | TDP1 (0.68) | TDP1MAPK1CYP3A4SMN1; SMN2EPHX2 | |
| SCHEMBL16933991 | 0.87 | LMNA (0.62) | MAPK1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL24089506 | 0.85 | TDP1 (0.63) | TDP1MAPK1LMNASMN1; SMN2EPHX2 | |
| SCHEMBL18896254 | 0.83 | LMNA (0.61) | MAPK1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL19043546 | 0.83 | MEN1 (0.63) | MAPK1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL8120575 | 0.83 | TDP1 (0.53) | TDP1MAPK1MEN1USP2ALDH1A1 | |
| SCHEMBL10284902 | 0.82 | S1PR1 (0.49) | MAPK1MEN1USP2ALDH1A1LMNA | |
| SCHEMBL5023581 | 0.82 | TDP1 (0.63) | TDP1MAPK1ALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-06 | — | — | US | disclosed |
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | TDP1 4127/4885MAPK1 1083/4885MEN1 2323/4885 |
| US-10369140-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | DGAT2, MGAT2, MGAT1 | TDP1 4127/4885MAPK1 1083/4885MEN1 2323/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.